Weakening assumptions in the evaluation of treatment effects in longitudinal randomized trials with truncation by death or other intercurrent events

Georgi Baklicharov, Kelly Van Lancker, Stijn Vansteelandt · 2025

Read Weakening assumptions in the evaluation of treatment effects in longitudinal randomized trials with truncation by death or other intercurrent events by Georgi Baklicharov, Kelly Van Lancker, Stijn Vansteelandt (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2509-10067.txt.

Introduction

Georgi Baklicharov and 2 co-authors propose a fairer way to judge treatments when some patients die or switch therapy mid-trial in a 2025 biostatistics paper. Such intercurrent events tangle intention-to-treat analysis, and standard fixes aim at hypothetical worlds or survivor-only effects that rest on claims nobody can verify. Sensitivity to hidden differences between groups then haunts every conclusion.

Their PLOT estimands compare matched treated and untreated patients at the last moment before either one hits an intercurrent event, using only information gathered earlier. In randomised trials those contrasts are identified with no structural assumptions, even when overlap between groups is severely broken. Tests and estimators built on the idea stay efficient and model-free, and simulations show leftover selection bias shrinking to a negligible size.

Catalog record

CREATORGeorgi Baklicharov, Kelly Van Lancker, Stijn Vansteelandt
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE83 KB
VERSION1.0
LICENSEhttp://creativecommons.org/licenses/by/4.0/
RIGHTSCC BY
SOURCEarXiv

Source: https://arxiv.org/abs/2509-10067

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Weakening assumptions in the evaluation of treatment effects in longitudinal randomized trials with truncation by death or other intercurrent events Georgi Baklicharov, Kelly Van Lancker, Stijn Vansteelandt Abstract Intercurrent events, such as treatment switching, rescue medication, or truncation by death, can complicate the interpretation of intention-to-treat (ITT) analyses in randomized clinical trials. Recent advances in causal inference address these challenges by targeting alternative estimands, such as hypothetical estimands or principal stratum estimands (e.g., survivor average causal effects). However, such approaches often require strong, unverifiable assumptions, partly due to limited data on time-varying confounders and the difficulty of adjusting for them. Additionally, strict trial protocols frequently lead to (near) violations of the positivity assumption, resulting in limited information for identifying these estimands. In this paper, we propose a novel approach that sidesteps these difficulties by focusing on testing the null hypothesis of no treatment effect in the presence of arbitrary intercurrent events, including truncation by death, using longitudinal trial data. Our key idea is to compare treated and untreated individuals, matched on baseline covariates, at the most recent time point before either experiences an intercurrent event. We refer to such contrasts as Pairwise Last Observation Time (PLOT) estimands. These estimands can be identified in randomized clinical trials without requiring additional structural assumptions, and even in the presence of the aforementioned positivity violations. However, they may still be susceptible to a form of residual selection bias. We show that this bias vanishes under the conditions typically required by alternative methods, and find it to be more generally small in extensive simulation studies. Building on this, we develop asymptotically efficient, model-free tests using data-adaptive estimation of nuisance parameters. We evaluate the method’s performance via simulation studies. 1 Introduction Many randomized trials are affected by intercurrent events (ICEs), such as treatment switching, rescue medication, truncation by death, etc., that occur after treatment initiation but before measurement of the outcome of interest. These events often complicate an intention-to-treat (ITT) analysis. For instance, an ineffective treatment may appear beneficial in an ITT analysis when patients cannot tolerate it well and therefore switch to a treatment external to the trial. Likewise, a beneficial treatment may appear harmful when patients on the control arm deteriorate and are therefore more often switched to a successful rescue medication. ITT analyses become especially subtle when study outcomes are truncated due to death. In that case, standard analyses, e.g., analyses within survivors, are prone to selection bias and may in particular suggest treatment effects on the study outcome, even when treatment only impacts survival ( Rosenbaum 1984 ) . Over the past decades, a rich literature has emerged to address ICEs in clinical trials; the ICH E9(R1) addendum on estimands and sensitivity analysis ( ICH 2019 ) in particular provides a structured framework for handling ICEs in trials. Much of this work focuses on hypothetical estimands which quantify what the ITT effect would have been had there been no ICEs (of a certain type) ( Michiels et al. 2021 ; Olarte Parra et al. 2023 ; Morgan et al. 2025 , e.g.,) . This is difficult to defend in the context of truncation by death ( Chaix et al. 2012 ) , where the central focus has instead been on principal stratum (PS) estimands ( Frangakis and Rubin 2004 ) , such as the survivor average causal effect (SACE) ( Robins 1986 ; Hayden et al. 2005 ; Tchetgen Tchetgen 2014 ; Wang et al. 2017 ) . This expresses the average treatment effect in the subgroup of individuals who would have survived until the end of study, regardless of their treatment assignment. These analyses go some way in addressing the above concerns, but also have major limitations. First, hypothetical estimands are difficult or even impossible to identify when, as often, there are (near) positivity violations that essentially prohibit people from not switching treatment; such violations are not uncommon as a result of strict protocol guidelines (e.g., on when rescue treatment is indicated) that make ICEs deterministic ( Olarte Parra et al. 2023 ) . Survivor average causal effects are likewise difficult to learn from data because the subgroup of individuals who would have survived until the end of study is unobserved. Strong identification conditions are therefore required, such as that all common causes of outcome and death have been measured at baseline; this does not align with the fact that many of these risk factors are time-varying, and themselves affected by treatment ( Vansteelandt and Van Lancker 2025 ) . In light of these complications, an alternative line of work has focused on composite estimands designed to avoid extrapolation beyond the observed data ( Mallinckrodt et al. 2019 ) . In the context of recurrent events, for instance, it is natural to contrast the expected number of events accumulated up to the time of death (or another intercurrent event), or the end of study, whichever occurs first, since no further events can occur thereafter. Such contrasts align with standard competing risk analyses and last observation carried forward (LOCF) approaches. However, hypothesis tests based on these estimands fail to distinguish whether potential treatment effects operate through the outcome process, through the ICE process (i.e., time to ICE), or both. To address this, while-alive or while-on-treatment estimands ( Schmidli et al. 2023 ) are often employed. These estimands compare the cumulative outcome accrued up to the last time point prior to death (or another ICE), normalized by the time elapsed since baseline. The resulting ratio is intended to adjust for the longer observation time that may arise in one treatment arm due to improved survival (or lower ICE rates). Nonetheless, this adjustment lacks a principled justification and may not adequately disentangle the underlying mechanisms of treatment effect ( Janvin et al. 2024 ) . We sidestep this issue by instead comparing treated and untreated individuals – matched on baseline covariates – at the last time point before either individual in the pair dies (or more generally, experiences an ICE). Unlike LOCF, while-alive or while-on-treatment estimands, this approach ensures that comparisons are made at the same time point, mitigating bias due to unequal survival times (or unequal times to ICEs). This leads to better interpretable treatment comparisons, but may nonetheless introduce a form of residual selection bias. We give insight into the nature of this bias, but find it to be small in extensive simulation studies, and show that it vanishes under the conditions typically assumed by existing approaches. Building on this insight, we construct asymptotically efficient, model-free tests of the null hypothesis of no treatment effect, using data-adaptive estimation of nuisance parameters. Our framework accommodates arbitrary (uncensored) outcomes measured in longitudinal clinical trials and arbitrary intercurrent events (including dropout and truncation by death). The remainder of the paper is organized as follows. In Section 2 , we introduce and motivate our estimands. Section 3 describes identification and estimation strategies. Section 4 reports simulation results to evaluate the finite-sample performance of the proposed methods in comparison with existing approaches. In Section 5 , we discuss assumptions under which valid hypothesis testing is possible. Section 6 concludes with a discussion of the main findings, limitations and directions for future work. Technical proofs and supplementary derivations

Read the complete text